HDAC inhibition induces microRNA-182 which targets Rad51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia

di Lai, Tsung-Huei, Ewald, Brett, Zecevic, Alma, Liu, Chaomei, Sulda, Melanie, Papaioannou, Dimitrios, Garzon, Ramiro, Blachly, J.S, Plunkett, William, Sampath, Deepa
Pubblicato in Clin Cancer Res (2016)

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

di Eisfeld, A-K, Mrózek, K, Kohlschmidt, J, Nicolet, D, Orwick, S, Walker, C J, Kroll, K W, Blachly, J S, Carroll, A J, Kolitz, J E, Powell, B L, Wang, E S, Stone, R M, de la Chapelle, A, Byrd, J C, Bloomfield, C D
Pubblicato in Leukemia (2017)

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

di Woyach, J.A., Ruppert, A.S., Heerema, N.A., Zhao, W., Booth, A.M., Ding, W., Bartlett, N.L., Brander, D.M., Barr, P.M., Rogers, K.A., Parikh, S.A., Coutre, S., Hurria, A., Brown, J.R., Lozanski, G., Blachly, J.S., Ozer, H.G., Major-Elechi, B., Fruth, B., Nattam, S., Larson, R.A., Erba, H., Litzow, M., Owen, C., Kuzma, C., Abramson, J.S., Little, R.F., Smith, S.E., Stone, R.M., Mandrekar, S.J., Byrd, J.C.
Pubblicato in N Engl J Med (2018)